|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brambilla E, Travis WD, Colby TV, Corrin B and Shimosato Y: The new World Health Organization classification of lung tumours. Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Steins M, Thomas M and Geißler M: Erlotinib. Recent Results Cancer Res. 211:1–17. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, et al Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica, : Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tagliamento M, Genova C, Rijavec E, Rossi G, Biello F, Dal Bello MG, Alama A, Coco S, Boccardo S and Grossi F: Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. Expert Opin Pharmacother. 19:2055–2062. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Garassino MC, Kawaguchi T, Gregorc V, Rulli E, Ando M, Marsoni S, Isa SI, Novello S, Farina G, Barni S, et al: Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: An individual patient data (IPD) analysis. ESMO Open. 3:e0003272018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nakahara Y, Hosomi Y, Saito M, Ogawa M, Hishima T, Okamura T, Sasaki J and Masuda N: Predictive significance of thyroid transcription factor-1 expression in patients with non-squamous non-small cell lung cancer with wild-type epidermal growth factor receptor treated with erlotinib. Mol Clin Oncol. 5:14–18. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hosny Mohammed K, Ewaz A, Cohen C and Siddiqui MT: Double staining: Diagnostic utility in non-small cell lung carcinoma in the era of tissue conservation. J Am Soc Cytopathol. 6:170–175. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun JM, Han J, Ahn JS, Park K and Ahn MJ: Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol. 6:1392–1399. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Puglisi F, Barbone F, Damante G, Bruckbauer M, Di Lauro V, Beltrami CA and Di Loreto C: Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma. Mod Pathol. 12:318–324. 1999.PubMed/NCBI
|
|
12
|
Elsamany SA, Al-Fayea TM, Alzahrani AS, Abozeed WN, Darwish W, Farooq MU, Almadani AS and Bukhari EA: Thyroid transcription factor-1 expression in advanced non- small cell lung cancer: Impact on survival outcome. Asian Pac J Cancer Prev. 16:2987–2991. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Berghmans T, Paesmans M, Mascaux C, Martin B, Meert AP, Haller A, Lafitte JJ and Sculier JP: Thyroid transcription factor 1 - a new prognostic factor in lung cancer: A meta-analysis. Ann Oncol. 17:1673–1676. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim JH, Kim HS, Kim BJ, Han B, Choi DR and Kwon JH: Prognostic impact of TTF-1 expression in non-squamous non-small-cell lung cancer: A meta-analysis. J Cancer. 9:4279–4286. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dötsch V, Andrews NC, Caput D and McKeon F: p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 2:305–316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma Y, Fan M, Dai L, Kang X, Liu Y, Sun Y, Xiong H, Liang Z, Yan W and Chen K: Expression of p63 and CK5/6 in early-stage lung squamous cell carcinoma is not only an early diagnostic indicator but also correlates with a good prognosis. Thorac Cancer. 6:288–295. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pelosi G, Pasini F, Olsen Stenholm C, Pastorino U, Maisonneuve P, Sonzogni A, Maffini F, Pruneri G, Fraggetta F, Cavallon A, et al: p63 immunoreactivity in lung cancer: Yet another player in the development of squamous cell carcinomas? J Pathol. 198:100–109. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matej R, Dundr P, Hornychova H, Ryska A and Ticha I: Nádory plic - doporučený postup pro bioptické vyšetření. Společnost českých patologů, 2019.
|
|
19
|
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowski M and Heigener D: Erlotinib in advanced non-small cell lung cancer: Efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol. 5:1616–1622. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Germonpré P and Van den Wyngaert T: Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability. PLoS One. 14:e02151352019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hirai F, Edagawa M, Shimamatsu S, Toyozawa R, Toyokawa G, Nosaki K, Yamaguchi M, Seto T, Takenoyama M and Ichinose Y: Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type. Oncol Lett. 14:306–312. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, Yang ZY, Mao C and Tang JL: The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget. 7:78985–78993. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Faehling M, Eckert R, Kuom S, Kamp T, Stoiber KM and Schumann C: Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. Oncology. 78:249–258. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang L, Lin M, Ruan WJ, Dong LL, Chen EG, Wu XH and Ying KJ: Nkx2-1: A novel tumor biomarker of lung cancer. J Zhejiang Univ Sci B. 13:855–866. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kerr KM: Personalized medicine for lung cancer: New challenges for pathology. Histopathology. 60:531–546. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Haque AK, Syed S, Lele SM, Freeman DH and Adegboyega PA: Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: Strong thyroid transcription factor-1 expression predicts better survival. Appl Immunohistochem Mol Morphol. 10:103–109. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu WY, Hu XF, Fang KX, Kong QQ, Cui R, Li HF, He JY, Zhang YK and Le HB: Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer. Histol Histopathol. 34:1269–1278. 2019.PubMed/NCBI
|
|
29
|
Fiala O, Pesek M, Skrickova J, Kolek V, Salajka F, Tomiskova M, Satankova M, Kultan J, Kuliskova J, Svaton M, et al: Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. Tumour Biol. 39:10104283176911862017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chatziandreou I, Tsioli P, Sakellariou S, Mourkioti I, Giannopoulou I, Levidou G, Korkolopoulou P, Patsouris E and Saetta AA: Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations. PLoS One. 10:e01338592015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zamboni M and Civitareale D: TTF-1/Nkx2.1 functional connection with mutated EGFR relies on LRIG1 and β-catenin pathways in lung cancer cells. Biochem Biophys Res Commun. 505:1027–1031. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Phelps CA, Lai SC and Mu D: Roles of Thyroid Transcription Factor 1 in Lung Cancer Biology. Vitam Horm. 106:517–544. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
34. Yoh K and Prywes R: Pathway Regulation of p63, a Director of Epithelial Cell Fate. Front Endocrinol (Lausanne). 6:512015.PubMed/NCBI
|
|
34
|
Holcakova J, Nekulova M, Orzol P, Nenutil R, Podhorec J, Svoboda M, Dvorakova P, Pjechova M, Hernychova L, Vojtesek B, et al: ΔNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells. Breast Cancer Res Treat. 163:475–484. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Patel TS, Shah MG, Gandhi JS and Patel P: Accuracy of cytology in sub typing non small cell lung carcinomas. Diagn Cytopathol. 45:598–603. 2017. View Article : Google Scholar : PubMed/NCBI
|
